On Feb. 23, 2022, Moderna and Thermo Fisher Scientific announced a 15-year strategic collaboration agreement to enable dedicated large-scale manufacturing in the U.S. of Spikevaxﾮ, Modernaﾒs COVID-19 vaccine, and other investigational mRNA medicines in its pipeline.